SG11201405226TA - Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof - Google Patents
Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereofInfo
- Publication number
- SG11201405226TA SG11201405226TA SG11201405226TA SG11201405226TA SG11201405226TA SG 11201405226T A SG11201405226T A SG 11201405226TA SG 11201405226T A SG11201405226T A SG 11201405226TA SG 11201405226T A SG11201405226T A SG 11201405226TA SG 11201405226T A SG11201405226T A SG 11201405226TA
- Authority
- SG
- Singapore
- Prior art keywords
- binding
- viruses
- molecules capable
- neutralizing influenza
- human
- Prior art date
Links
- 241000713196 Influenza B virus Species 0.000 title 1
- 230000003472 neutralizing effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1018—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6839—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting material from viruses
- A61K47/6841—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting material from viruses the antibody targeting a RNA virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/11—Orthomyxoviridae, e.g. influenza virus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261608414P | 2012-03-08 | 2012-03-08 | |
EP12158525 | 2012-03-08 | ||
PCT/EP2013/054606 WO2013132007A1 (fr) | 2012-03-08 | 2013-03-07 | Molécules de liaison humaines aptes à se lier à des virus de la grippe b et de neutraliser des virus de la grippe b, et leurs utilisations |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201405226TA true SG11201405226TA (en) | 2014-11-27 |
Family
ID=49115966
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201405226TA SG11201405226TA (en) | 2012-03-08 | 2013-03-07 | Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof |
Country Status (19)
Country | Link |
---|---|
US (5) | US8834881B2 (fr) |
EP (1) | EP2822968B1 (fr) |
JP (1) | JP6328061B2 (fr) |
KR (1) | KR102050615B1 (fr) |
CN (2) | CN108640989B (fr) |
AR (1) | AR091316A1 (fr) |
AU (2) | AU2013229488B2 (fr) |
CA (1) | CA2865594C (fr) |
DK (1) | DK2822968T3 (fr) |
EA (1) | EA028433B1 (fr) |
ES (1) | ES2664625T3 (fr) |
HK (1) | HK1200176A1 (fr) |
MX (1) | MX360056B (fr) |
MY (1) | MY170407A (fr) |
NZ (1) | NZ628382A (fr) |
PH (2) | PH12014501776B1 (fr) |
SG (1) | SG11201405226TA (fr) |
TW (1) | TWI628190B (fr) |
WO (1) | WO2013132007A1 (fr) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IN2014CN04742A (fr) | 2011-11-28 | 2015-09-18 | Crucell Holland Bv | |
DK2793945T3 (en) | 2011-12-05 | 2018-09-03 | Trellis Bioscience Llc | USEFUL ANTIBODIES FOR PASSIVE INFLUENZA IMMUNIZATION |
MY170407A (en) | 2012-03-08 | 2019-07-27 | Crucell Holland Bv | Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof |
US9969794B2 (en) | 2012-05-10 | 2018-05-15 | Visterra, Inc. | HA binding agents |
RU2701694C2 (ru) | 2013-03-14 | 2019-09-30 | Контрафект Корпорейшн | Композиции и способы, основанные на нейтрализующих антителах, доставляемых интраназально, для улучшенной терапевтической эффективности |
US9624272B2 (en) | 2013-03-14 | 2017-04-18 | University Of Washington Through Its Center For Commercialization | Polypeptides for treating and/or limiting influenza infection |
RU2683498C2 (ru) | 2013-10-02 | 2019-03-28 | МЕДИММЬЮН, ЭлЭлСи | Нейтрализующие антитела к вирусу гриппа а и пути их применения |
US20160304586A1 (en) * | 2013-12-05 | 2016-10-20 | Crucell Holland B.V. | Process for preparing influenza vaccines |
CN106795216B (zh) * | 2014-02-04 | 2021-04-20 | 抗非特公司 | 可用于被动流感免疫的抗体及其组合物、组合和使用方法 |
US10639370B2 (en) | 2014-02-04 | 2020-05-05 | Contrafect Corporation | Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof |
CA2942820A1 (fr) * | 2014-03-27 | 2015-10-01 | Genentech, Inc. | Anticorps hemagglutinine diriges contre le virus de la grippe b et methodes d'utilisation |
RU2739952C2 (ru) * | 2014-07-15 | 2020-12-30 | МЕДИММЬЮН, ЭлЭлСи | Нейтрализующие антитела к вирусу гриппа b и пути их применения |
TWI702229B (zh) | 2014-12-19 | 2020-08-21 | 美商再生元醫藥公司 | 流行性感冒病毒血球凝集素之人類抗體 |
MY186585A (en) | 2015-02-05 | 2021-07-28 | Janssen Vaccines & Prevention Bv | Binding molecules directed against influenza hemagglutinin and uses thereof |
CA2985402A1 (fr) * | 2015-05-11 | 2016-11-17 | Janssen Vaccines & Prevention B.V. | Composes peptidomimetiques neutralisant le virus influenza |
AU2016275909A1 (en) | 2015-05-13 | 2017-11-09 | The Trustees Of The University Of Pennsylvania | AAV-mediated expression of anti-influenza antibodies and methods of use thereof |
SI3303384T1 (sl) * | 2015-06-01 | 2021-11-30 | Medimmune Llc | Nevtralizirajoče vezavne molekule proti-influenci in njihova uporaba |
WO2016192652A1 (fr) * | 2015-06-03 | 2016-12-08 | 厦门大学 | Anticorps monoclonal anti-grippe b à large spectre et utilisations de celui-ci |
JP2017062300A (ja) * | 2015-09-24 | 2017-03-30 | セイコーエプソン株式会社 | 半導体装置、システム、電子機器、及び、音声認識方法 |
US10513553B2 (en) | 2015-11-13 | 2019-12-24 | Visterra, Inc. | Compositions and methods for treating and preventing influenza |
EP3402513A4 (fr) | 2016-01-13 | 2019-10-23 | Medlmmune, LLC | Méthode de traitement de la grippe a |
US10703803B2 (en) | 2016-03-01 | 2020-07-07 | Janssen Vaccines & Prevention B.V. | Human neutralizing antibodies binding to influenza B neuraminidase |
WO2018027124A1 (fr) * | 2016-08-05 | 2018-02-08 | Medimmune, Llc | Anticorps anti-o2 et utilisations associées |
US11117956B2 (en) | 2016-10-19 | 2021-09-14 | Medimmune, Llc | Anti-O1 antibodies and uses thereof |
CA3052487A1 (fr) | 2017-02-28 | 2018-09-07 | The Trustees Of The University Of Pennsylvania | Vaccins contre la grippe bases sur des vecteurs aav |
US11827906B2 (en) | 2017-02-28 | 2023-11-28 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (AAV) clade f vector and uses therefor |
JOP20190200A1 (ar) | 2017-02-28 | 2019-08-27 | Univ Pennsylvania | تركيبات نافعة في معالجة ضمور العضل النخاعي |
BR112019020148A2 (pt) | 2017-04-13 | 2020-05-05 | Cadila Healthcare Ltd | peptídeo |
EA202091563A1 (ru) | 2018-01-26 | 2020-10-08 | Регенерон Фармасьютикалз, Инк. | Человеческие антитела к гемагглютинину вируса гриппа |
BR112021000383A2 (pt) * | 2018-07-11 | 2021-04-06 | Momenta Pharmaceuticals, Inc. | Composições e métodos relacionados a construtos do domínio de ligação fc-antígeno manipulado direcionado a pd-l1 |
AU2020248404A1 (en) | 2019-03-25 | 2021-09-30 | Visterra, Inc. | Compositions and methods for treating and preventing influenza |
WO2021195326A1 (fr) * | 2020-03-26 | 2021-09-30 | Vanderbilt University | Anticorps monoclonaux humains dirigés contre le coronavirus du syndrome respiratoire aigu sévère 2 (sras-cov-2) |
WO2021201677A1 (fr) | 2020-04-01 | 2021-10-07 | Kiadis Pharma Intellectual Property B.V. | Compositions et procédés ciblant la grippe |
CA3177030A1 (fr) | 2020-04-27 | 2021-11-04 | Aaron Sato | Bibliotheques d'acides nucleiques variants de coronavirus |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ207394A (en) | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
NL9101953A (nl) | 1991-11-21 | 1993-06-16 | Seed Capital Investments | Testinrichting omvattende een plaat met een veelvoud van putjes met een bijbehorende doseerinrichting, alsmede een kit die deze inrichtingen omvat en toepassing van de inrichtingen. |
US6248780B1 (en) | 1998-10-01 | 2001-06-19 | Duquesne University Of The Holy Ghost | Compounds for the treatment of estrogen-dependent illnesses and methods for making and using the same |
EP1533380B1 (fr) | 1999-04-15 | 2009-11-04 | Crucell Holland B.V. | Production de protéine de recombinaison dans une cellule humaine comprenant au moins une protéine E1 d'adénovirus |
WO2002103012A1 (fr) | 2001-06-15 | 2002-12-27 | Crucell Holland B.V. | Phages chimeriques |
US7135174B2 (en) * | 2002-01-07 | 2006-11-14 | Amgen Fremont, Inc. | Antibodies directed to PDGFD and uses thereof |
ES2527503T3 (es) * | 2005-03-08 | 2015-01-26 | Medimmune, Llc | Virus influenza reordenantes |
WO2006124269A2 (fr) | 2005-05-16 | 2006-11-23 | Amgen Fremont Inc. | Anticorps monoclonaux humains se fixant a l'antigene-1 tres tardif pour le traitement de l'inflammation ainsi que d'autres troubles |
TW200815474A (en) | 2006-08-03 | 2008-04-01 | Astrazeneca Ab | Antibodies alphaVbeta6 and uses thereof |
AU2007293662B2 (en) | 2006-09-07 | 2012-10-04 | Crucell Holland B.V. | Human binding molecules capable of neutralizing influenza virus H5N1 and uses thereof |
US8846867B2 (en) | 2007-06-26 | 2014-09-30 | The Trustees Of The University Of Pennsylvania | Isolation of anti-desmoglein 1 antibodies by phage display of pemphigus foliaceus autoantibodies |
FR2921928B1 (fr) * | 2007-10-08 | 2011-03-04 | Sanofi Pasteur | Anticorps monoclonaux specifiques de l'hemagglutinine du virus grippal |
KR101732056B1 (ko) * | 2008-07-25 | 2017-05-02 | 인스티튜트 포 리서치 인 바이오메드슨 | 중화 항-인플루엔자 a 바이러스 항체 및 이의 용도 |
EP2179811B1 (fr) | 2008-10-21 | 2018-10-03 | Agie Charmilles SA | Procédé et appareil de commande d'un procédé d'usinage de décharge électrique |
EP2842573B1 (fr) * | 2008-11-07 | 2017-09-27 | Galaxy Biotech, LLC | Anticorps monoclonaux dirigés contre le récepteur 2 du facteur de croissance des fibroblastes |
WO2010073647A1 (fr) * | 2008-12-25 | 2010-07-01 | 国立大学法人大阪大学 | Anticorps humain anti-virus de la grippe humaine |
CN102448986B (zh) | 2009-05-11 | 2015-11-25 | 克鲁塞尔荷兰公司 | 能中和流感病毒h3n2的人结合分子及其应用 |
AU2010254136B2 (en) * | 2009-05-26 | 2016-09-29 | Mount Sinai School Of Medicine | Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof |
US8926976B2 (en) * | 2009-09-25 | 2015-01-06 | Xoma Technology Ltd. | Modulators |
WO2013114885A1 (fr) * | 2012-01-31 | 2013-08-08 | Osaka University | Anticorps monoclonaux humains protecteurs à large spectre contre le virus de la grippe b et méthodes d'utilisation correspondantes |
MY170407A (en) | 2012-03-08 | 2019-07-27 | Crucell Holland Bv | Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof |
-
2013
- 2013-03-07 MY MYPI2014702487A patent/MY170407A/en unknown
- 2013-03-07 CN CN201810486503.2A patent/CN108640989B/zh active Active
- 2013-03-07 KR KR1020147025832A patent/KR102050615B1/ko active IP Right Grant
- 2013-03-07 DK DK13708411.7T patent/DK2822968T3/en active
- 2013-03-07 SG SG11201405226TA patent/SG11201405226TA/en unknown
- 2013-03-07 MX MX2014010755A patent/MX360056B/es active IP Right Grant
- 2013-03-07 JP JP2014560375A patent/JP6328061B2/ja active Active
- 2013-03-07 AU AU2013229488A patent/AU2013229488B2/en active Active
- 2013-03-07 EP EP13708411.7A patent/EP2822968B1/fr active Active
- 2013-03-07 WO PCT/EP2013/054606 patent/WO2013132007A1/fr active Application Filing
- 2013-03-07 EA EA201491656A patent/EA028433B1/ru not_active IP Right Cessation
- 2013-03-07 ES ES13708411.7T patent/ES2664625T3/es active Active
- 2013-03-07 US US13/789,284 patent/US8834881B2/en active Active
- 2013-03-07 CN CN201380012721.8A patent/CN104169298B/zh active Active
- 2013-03-07 CA CA2865594A patent/CA2865594C/fr active Active
- 2013-03-07 NZ NZ628382A patent/NZ628382A/en not_active IP Right Cessation
- 2013-03-08 TW TW102108417A patent/TWI628190B/zh not_active IP Right Cessation
- 2013-03-08 AR ARP130100759 patent/AR091316A1/es active IP Right Grant
- 2013-10-10 US US14/051,365 patent/US8852595B2/en active Active
-
2014
- 2014-07-03 US US14/323,908 patent/US9005621B2/en active Active
- 2014-08-07 PH PH12014501776A patent/PH12014501776B1/en unknown
- 2014-10-13 US US14/513,162 patent/US9200064B2/en active Active
-
2015
- 2015-01-20 HK HK15100646.1A patent/HK1200176A1/xx not_active IP Right Cessation
- 2015-09-17 US US14/857,587 patent/US20160002318A1/en not_active Abandoned
- 2015-11-09 PH PH12015502553A patent/PH12015502553A1/en unknown
-
2018
- 2018-03-07 AU AU2018201647A patent/AU2018201647B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201405226TA (en) | Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof | |
HK1213591A1 (zh) | 生物粘合劑的製備和應用 | |
HK1210216A1 (en) | Double-stranded oligonucleotide molecules to p53 and methods of use thereof p53 | |
HK1202123A1 (en) | Human antibodies to fel d1 and methods of use thereof fel d1 | |
IL216222A0 (en) | Human binding molecules capable of neutralizing influenza virus h3n2 and uses thereof | |
HK1206037A1 (en) | Human antibodies to gfr3 and methods of use thereof gfr3 | |
ZA201501674B (en) | Use of semaphorin-4d binding molecules to promote neurogenesis following stroke | |
GB201506561D0 (en) | Treatment of amblyopia | |
PL2892556T3 (pl) | Kompozycje i sposoby odnoszące się do leczenia chorób | |
ZA201501601B (en) | Virus purification and formulation process | |
HK1206783A1 (en) | Nucleic acid molecule binding to influenza virus and use therefor | |
HK1201283A1 (en) | Influenza c virus and vaccine | |
ZA201408128B (en) | Etract of greyia radlkoferi and use thereof | |
HUE036419T2 (hu) | Légzõszervi depresszió kezelése | |
GB201207907D0 (en) | Treatment of depression | |
IL234446B (en) | Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof | |
SG11201504779YA (en) | Methods and compositions relating to treatment of cancer | |
ZA201309304B (en) | Human binding molecules capable of neutralizing influenza a viruses of phylogenetic group 1 and phylogenetic group 2 and influenza b viruses |